nct_id
stringlengths 11
11
| nlm_download_date_description
float64 | study_first_submitted_date
stringlengths 10
10
| results_first_submitted_date
stringlengths 10
10
⌀ | disposition_first_submitted_date
stringclasses 493
values | last_update_submitted_date
stringlengths 10
10
| study_first_submitted_qc_date
stringlengths 10
10
| study_first_posted_date
stringlengths 10
10
| study_first_posted_date_type
stringclasses 2
values | results_first_submitted_qc_date
stringlengths 10
10
⌀ | results_first_posted_date
stringlengths 10
10
⌀ | results_first_posted_date_type
stringclasses 2
values | disposition_first_submitted_qc_date
stringclasses 321
values | disposition_first_posted_date
stringclasses 478
values | disposition_first_posted_date_type
stringclasses 2
values | last_update_submitted_qc_date
stringlengths 10
10
| last_update_posted_date
stringlengths 10
10
| last_update_posted_date_type
stringclasses 2
values | start_month_year
stringlengths 7
10
⌀ | start_date_type
stringclasses 2
values | start_date
stringlengths 10
10
⌀ | verification_month_year
stringclasses 151
values | verification_date
stringclasses 151
values | completion_month_year
stringlengths 7
10
| completion_date_type
stringclasses 2
values | completion_date
stringlengths 10
10
| primary_completion_month_year
stringlengths 7
10
| primary_completion_date_type
stringclasses 2
values | primary_completion_date
stringlengths 10
10
| target_duration
float64 | study_type
stringclasses 1
value | acronym
stringlengths 2
14
⌀ | baseline_population
stringlengths 2
501
⌀ | brief_title
stringlengths 18
300
| official_title
stringlengths 28
563
⌀ | overall_status
stringclasses 4
values | last_known_status
float64 | phase
stringclasses 7
values | enrollment
float64 0
477k
| enrollment_type
stringclasses 2
values | source
stringlengths 3
107
| limitations_and_caveats
stringlengths 10
503
⌀ | number_of_arms
float64 1
27
⌀ | number_of_groups
float64 | why_stopped
stringlengths 3
252
⌀ | has_expanded_access
stringclasses 2
values | expanded_access_type_individual
float64 | expanded_access_type_intermediate
float64 | expanded_access_type_treatment
float64 | has_dmc
stringclasses 2
values | is_fda_regulated_drug
stringclasses 2
values | is_fda_regulated_device
stringclasses 2
values | is_unapproved_device
stringclasses 1
value | is_ppsd
float64 | is_us_export
stringclasses 2
values | biospec_retention
float64 | biospec_description
float64 | ipd_time_frame
stringclasses 442
values | ipd_access_criteria
stringclasses 465
values | ipd_url
stringclasses 124
values | plan_to_share_ipd
stringclasses 3
values | plan_to_share_ipd_description
stringlengths 3
998
⌀ | created_at
stringclasses 526
values | updated_at
stringclasses 526
values | source_class
stringclasses 8
values | delayed_posting
float64 | expanded_access_nctid
stringclasses 80
values | expanded_access_status_for_nctid
stringclasses 4
values | fdaaa801_violation
float64 | baseline_type_units_analyzed
stringclasses 11
values | patient_registry
float64 | completion_year
int64 2.02k
2.02k
| labels
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01236547 | null | 2010-11-05 | 2021-03-02 | null | 2022-06-28 | 2010-11-05 | 2010-11-07 | ESTIMATED | 2021-04-16 | 2021-05-14 | ACTUAL | null | null | null | 2022-06-28 | 2022-07-19 | ACTUAL | 2010-10-28 | ACTUAL | 2010-10-28 | 2022-05 | 2022-05-31 | 2022-05-20 | ACTUAL | 2022-05-20 | 2020-03-09 | ACTUAL | 2020-03-09 | null | INTERVENTIONAL | null | Eligible participants | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer | COMPLETED | null | PHASE2 | 123 | ACTUAL | National Cancer Institute (NCI) | One run-in arm was originally planned; more run-in arms added due to amendments to the protocol regimen unrelated to toxicities. In addition, due to higher than projected rates of ineligibility and consent withdrawals, phase II final analysis was amended to be time-driven (3 years of potential follow-up for all eligible phase II participants) instead of event driven (71 deaths of eligible phase II participants), reducing power from 80% (one-sided alpha 0.15) to 77% (one-sided alpha 0.1379), | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | NIH | null | null | null | null | null | null | 2,022 | 1 |
NCT03277586 | null | 2017-09-01 | null | null | 2021-01-13 | 2017-09-06 | 2017-09-11 | ACTUAL | null | null | null | null | null | null | 2021-01-13 | 2021-01-15 | ACTUAL | 2018-05-29 | ACTUAL | 2018-05-29 | 2021-01 | 2021-01-31 | 2020-11-30 | ACTUAL | 2020-11-30 | 2020-11-30 | ACTUAL | 2020-11-30 | null | INTERVENTIONAL | EPSD | null | Effects of Probiotics on Symptoms of Depression | Effects of Probiotics on Symptoms of Depression | TERMINATED | null | PHASE3 | 28 | ACTUAL | Queen's University | null | 2 | null | COVID-19 | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03757715 | null | 2018-11-27 | 2022-03-20 | null | 2022-08-12 | 2018-11-27 | 2018-11-29 | ACTUAL | 2022-08-12 | 2022-08-31 | ACTUAL | null | null | null | 2022-08-12 | 2022-08-31 | ACTUAL | 2019-05-20 | ACTUAL | 2019-05-20 | 2022-08 | 2022-08-31 | 2021-04-12 | ACTUAL | 2021-04-12 | 2021-03-12 | ACTUAL | 2021-03-12 | null | INTERVENTIONAL | null | null | Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery | The Role of Regional Anesthesia to Reduce Opioid Requirements Following Functional Endoscopic Sinus Surgery (FESS) | COMPLETED | null | PHASE4 | 46 | ACTUAL | University of Alabama at Birmingham | null | 2 | null | null | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 03:57:19.412252 | 2024-10-17 03:57:19.412252 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT05272813 | null | 2022-02-18 | null | null | 2024-07-16 | 2022-02-28 | 2022-03-09 | ACTUAL | null | null | null | null | null | null | 2024-07-16 | 2024-07-18 | ACTUAL | 2022-04-28 | ACTUAL | 2022-04-28 | 2024-07 | 2024-07-31 | 2023-11-28 | ACTUAL | 2023-11-28 | 2023-11-28 | ACTUAL | 2023-11-28 | null | INTERVENTIONAL | null | null | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | TERMINATED | null | PHASE1/PHASE2 | 13 | ACTUAL | MingSight Pharmaceuticals, Inc | null | 4 | null | The study is terminated due to major protocol revisions. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 16:13:18.027461 | 2024-10-16 16:13:18.027461 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT05260541 | null | 2022-02-18 | null | null | 2022-11-28 | 2022-02-18 | 2022-03-02 | ACTUAL | null | null | null | null | null | null | 2022-11-28 | 2022-12-01 | ACTUAL | 2022-01-25 | ACTUAL | 2022-01-25 | 2022-11 | 2022-11-30 | 2022-09-23 | ACTUAL | 2022-09-23 | 2022-08-01 | ACTUAL | 2022-08-01 | null | INTERVENTIONAL | null | null | A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder | A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder | TERMINATED | null | PHASE2 | 11 | ACTUAL | Praxis Precision Medicines | null | 3 | null | No longer developing for this indication | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT05556356 | null | 2022-09-22 | null | null | 2024-10-01 | 2022-09-22 | 2022-09-27 | ACTUAL | null | null | null | null | null | null | 2024-10-01 | 2024-10-08 | ACTUAL | 2022-09-13 | ACTUAL | 2022-09-13 | 2024-10 | 2024-10-31 | 2024-05-06 | ACTUAL | 2024-05-06 | 2024-05-06 | ACTUAL | 2024-05-06 | null | INTERVENTIONAL | null | null | Effect of Perioperative Acetaminophen Dosing on Patients Undergoing Surgical Treatment of Basilar Thumb Arthritis | Effect of Perioperative Acetaminophen Dosing on Patients Undergoing Surgical Treatment of Basilar Thumb Arthritis | TERMINATED | null | PHASE4 | 23 | ACTUAL | Indiana Hand to Shoulder Center | null | 2 | null | Physician decision | f | null | null | null | f | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04888585 | null | 2021-05-13 | 2024-08-19 | 2023-07-14 | 2024-09-30 | 2021-05-13 | 2021-05-17 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | 2024-10-08 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-06-23 | ACTUAL | 2021-06-23 | 2024-09 | 2024-09-30 | 2023-08-04 | ACTUAL | 2023-08-04 | 2022-08-25 | ACTUAL | 2022-08-25 | null | INTERVENTIONAL | null | The Intent-to-treat (ITT) Population included all participants who were randomized and received at least 1 dose of study drug (N=472). The ITT Population was used for all efficacy analyses.~The Placebo group from Period 1 was re-randomized to either 150 mg or 340 mg for the Long-Term Extension Periods 1 and 2. For the other groups from Period 1 receiving ABBV-154, participants continued receiving ABBV-154 at the same dose and dosing regimen as in Period 1. | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) | TERMINATED | null | PHASE2 | 473 | ACTUAL | AbbVie | null | 5 | null | Business decision | f | null | null | null | t | t | f | null | null | f | null | null | For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/ | Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/ | https://vivli.org/ourmember/abbvie/ | YES | AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT03086343 | null | 2017-03-20 | 2020-05-08 | null | 2024-07-17 | 2017-03-20 | 2017-03-22 | ACTUAL | 2020-05-28 | 2020-06-04 | ACTUAL | null | null | null | 2024-07-17 | 2024-07-18 | ACTUAL | 2017-05-09 | ACTUAL | 2017-05-09 | 2024-07 | 2024-07-31 | 2023-06-06 | ACTUAL | 2023-06-06 | 2019-06-13 | ACTUAL | 2019-06-13 | null | INTERVENTIONAL | null | Full Analysis Set: all randomized participants who received at least one dose of study drug during Period 1 | A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs | A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | COMPLETED | null | PHASE3 | 657 | ACTUAL | AbbVie | null | 4 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. | Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link. | https://vivli.org/ourmember/abbvie/ | YES | AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT04379492 | null | 2020-05-05 | null | null | 2020-10-29 | 2020-05-06 | 2020-05-07 | ACTUAL | null | null | null | null | null | null | 2020-10-29 | 2020-10-30 | ACTUAL | 2020-05-05 | ACTUAL | 2020-05-05 | 2020-10 | 2020-10-31 | 2020-09-25 | ACTUAL | 2020-09-25 | 2020-09-25 | ACTUAL | 2020-09-25 | null | INTERVENTIONAL | null | null | A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 | Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Memorial Sloan Kettering Cancer Center | null | 2 | null | Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2 infection. No pts have been enrolled. | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | YES | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04749433 | null | 2021-01-29 | null | null | 2024-10-03 | 2021-02-08 | 2021-02-11 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2021-09-01 | ACTUAL | 2021-09-01 | 2024-10 | 2024-10-31 | 2023-03-30 | ACTUAL | 2023-03-30 | 2023-03-30 | ACTUAL | 2023-03-30 | null | INTERVENTIONAL | null | null | Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS | A Phase 1 Study to Assess the Safety and Tolerability of PET Imaging With [11C]CPPC [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] Radioligand in Patients With Amyotrophic Lateral Sclerosis | TERMINATED | null | PHASE1 | 4 | ACTUAL | Johns Hopkins University | null | 2 | null | study stopped to enhance protocol and resume under different sponsor | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04924413 | null | 2021-05-31 | null | null | 2024-07-02 | 2021-06-09 | 2021-06-14 | ACTUAL | null | null | null | null | null | null | 2024-07-02 | 2024-07-03 | ACTUAL | 2021-07-01 | ACTUAL | 2021-07-01 | 2024-07 | 2024-07-31 | 2024-07-02 | ACTUAL | 2024-07-02 | 2024-07-02 | ACTUAL | 2024-07-02 | null | INTERVENTIONAL | null | null | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | TERMINATED | null | PHASE2 | 9 | ACTUAL | Henan Cancer Hospital | null | 1 | null | Slow enrollment | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER_GOV | null | null | null | null | null | null | 2,024 | 0 |
NCT00281658 | null | 2006-01-23 | 2011-05-05 | null | 2023-02-09 | 2006-01-24 | 2006-01-25 | ESTIMATED | 2011-05-05 | 2011-06-01 | ESTIMATED | null | null | null | 2023-02-09 | 2023-02-10 | ACTUAL | 2006-01-02 | ACTUAL | 2006-01-02 | 2023-02 | 2023-02-28 | 2021-11-23 | ACTUAL | 2021-11-23 | 2010-06-18 | ACTUAL | 2010-06-18 | null | INTERVENTIONAL | null | null | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer | COMPLETED | null | PHASE3 | 444 | ACTUAL | Novartis | The data collected for China patients after 01JUL2019 were excluded from analysis due to local regulations in China. | 4 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04984876 | null | 2021-07-29 | 2024-05-22 | null | 2024-09-13 | 2021-07-29 | 2021-08-02 | ACTUAL | 2024-09-13 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-13 | 2024-10-08 | ACTUAL | 2021-12-07 | ACTUAL | 2021-12-07 | 2024-09 | 2024-09-30 | 2023-11-27 | ACTUAL | 2023-11-27 | 2023-11-27 | ACTUAL | 2023-11-27 | null | INTERVENTIONAL | null | null | Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy | A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy | TERMINATED | null | PHASE3 | 211 | ACTUAL | Novartis | null | 5 | null | Study terminated by sponsor | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT05269121 | null | 2022-02-25 | null | null | 2024-02-21 | 2022-02-25 | 2022-03-07 | ACTUAL | null | null | null | null | null | null | 2024-02-21 | 2024-02-22 | ACTUAL | 2022-09 | ESTIMATED | 2022-09-30 | 2024-02 | 2024-02-29 | 2024-11 | ESTIMATED | 2024-11-30 | 2023-11 | ESTIMATED | 2023-11-30 | null | INTERVENTIONAL | ACTIVE1 | null | Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections | An Open-Label Multicenter Study to Evaluate the Safety and Efficacy of PhageBank™ Phage Therapy in Conjunction With Debridement, Antibiotics, and Implant Retention (DAIR) for Patients With First Time Culture Proven Chronic Prosthetic Joint Infection | WITHDRAWN | null | PHASE1/PHASE2 | 0 | ACTUAL | Adaptive Phage Therapeutics, Inc. | null | 1 | null | Sponsor Decision | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT02767921 | null | 2016-05-06 | null | null | 2021-11-15 | 2016-05-06 | 2016-05-11 | ESTIMATED | null | null | null | null | null | null | 2021-11-15 | 2021-11-24 | ACTUAL | 2016-08-02 | ACTUAL | 2016-08-02 | 2021-11 | 2021-11-30 | 2021-11-15 | ACTUAL | 2021-11-15 | 2020-01-28 | ACTUAL | 2020-01-28 | null | INTERVENTIONAL | null | null | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers | TERMINATED | null | PHASE1 | 2 | ACTUAL | University of Southern California | null | 1 | null | Insufficient accrual | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03772288 | null | 2018-12-10 | null | null | 2023-02-06 | 2018-12-10 | 2018-12-11 | ACTUAL | null | null | null | null | null | null | 2023-02-06 | 2023-02-08 | ACTUAL | 2019-04-03 | ACTUAL | 2019-04-03 | 2023-02 | 2023-02-28 | 2021-11-17 | ESTIMATED | 2021-11-17 | 2021-11-10 | ESTIMATED | 2021-11-10 | null | INTERVENTIONAL | null | null | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | A Phase 1b Study of TAK-659 in Combination With NKTR-214 in Patients With Advanced Non-Hodgkin Lymphoma | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Calithera Biosciences, Inc | null | 2 | null | Business Decision: No Safety or Efficacy Concerns | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment. | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04886596 | null | 2021-04-29 | 2023-04-10 | null | 2024-09-20 | 2021-05-10 | 2021-05-14 | ACTUAL | 2023-07-14 | 2023-08-04 | ACTUAL | null | null | null | 2024-09-20 | 2024-10-08 | ACTUAL | 2021-05-25 | ACTUAL | 2021-05-25 | 2024-09 | 2024-09-30 | 2024-05-31 | ACTUAL | 2024-05-31 | 2022-04-11 | ACTUAL | 2022-04-11 | null | INTERVENTIONAL | null | null | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above | COMPLETED | null | PHASE3 | 26,668 | ACTUAL | GlaxoSmithKline | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study. | Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months. | null | YES | IPD for this study will be made available via the Clinical Study Data Request site. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT04172844 | null | 2019-11-20 | null | null | 2024-05-31 | 2019-11-20 | 2019-11-21 | ACTUAL | null | null | null | null | null | null | 2024-05-31 | 2024-06-04 | ACTUAL | 2020-01-13 | ACTUAL | 2020-01-13 | 2024-05 | 2024-05-31 | 2022-02-27 | ACTUAL | 2022-02-27 | 2021-12-12 | ACTUAL | 2021-12-12 | null | INTERVENTIONAL | PAVE | null | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML) | TERMINATED | null | PHASE1 | 16 | ACTUAL | Medical College of Wisconsin | null | 2 | null | Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03677401 | null | 2018-09-17 | 2020-10-06 | null | 2021-05-18 | 2018-09-17 | 2018-09-19 | ACTUAL | 2020-10-06 | 2020-10-28 | ACTUAL | null | null | null | 2021-05-18 | 2021-05-20 | ACTUAL | 2018-08-29 | ACTUAL | 2018-08-29 | 2021-05 | 2021-05-31 | 2020-02-06 | ACTUAL | 2020-02-06 | 2020-01-09 | ACTUAL | 2020-01-09 | null | INTERVENTIONAL | null | null | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis | COMPLETED | null | PHASE3 | 295 | ACTUAL | Vyne Therapeutics Inc. | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT05457491 | null | 2022-07-11 | 2023-01-05 | null | 2024-09-24 | 2022-07-11 | 2022-07-14 | ACTUAL | 2024-09-24 | 2024-10-04 | ACTUAL | null | null | null | 2024-09-24 | 2024-10-04 | ACTUAL | 2021-10-01 | ACTUAL | 2021-10-01 | 2024-09 | 2024-09-30 | 2022-07-07 | ACTUAL | 2022-07-07 | 2022-07-07 | ACTUAL | 2022-07-07 | null | INTERVENTIONAL | null | null | Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) | Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) | TERMINATED | null | PHASE1 | 56 | ACTUAL | Mayo Clinic | Study was terminated early per Principal Investigator | 1 | null | Principal Investigator discretion | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02451943 | null | 2015-05-20 | 2019-11-27 | null | 2024-09-20 | 2015-05-20 | 2015-05-22 | ESTIMATED | 2019-11-27 | 2019-12-17 | ACTUAL | null | null | null | 2024-09-20 | 2024-10-08 | ACTUAL | 2015-09-14 | ACTUAL | 2015-09-14 | 2024-09 | 2024-09-30 | 2024-06-27 | ACTUAL | 2024-06-27 | 2018-12-05 | ACTUAL | 2018-12-05 | null | INTERVENTIONAL | ANNOUNCE | All randomized participants. | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma | COMPLETED | null | PHASE3 | 509 | ACTUAL | Eli Lilly and Company | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting. | A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement. | https://vivli.org/ | YES | Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT04672954 | null | 2020-12-14 | 2023-07-31 | null | 2023-07-31 | 2020-12-14 | 2020-12-17 | ACTUAL | 2023-07-31 | 2024-03-08 | ACTUAL | null | null | null | 2023-07-31 | 2024-03-08 | ACTUAL | 2021-01-07 | ACTUAL | 2021-01-07 | 2023-07 | 2023-07-31 | 2021-07-01 | ACTUAL | 2021-07-01 | 2021-07-01 | ACTUAL | 2021-07-01 | null | INTERVENTIONAL | null | Treated set (TS): all subjects who were entered and treated with one dose of study drug (i.e. verum or placebo). | A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid | Pharmacokinetics and Pharmacodynamic Effects of Different Single Oral Doses of BI 474121 in Healthy Male Subjects | COMPLETED | null | PHASE1 | 24 | ACTUAL | Boehringer Ingelheim | null | 5 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03797872 | null | 2018-12-18 | 2021-02-15 | null | 2021-05-07 | 2019-01-04 | 2019-01-09 | ACTUAL | 2021-05-07 | 2021-05-10 | ACTUAL | null | null | null | 2021-05-07 | 2021-05-10 | ACTUAL | 2019-04-17 | ACTUAL | 2019-04-17 | 2020-03 | 2020-03-31 | 2020-07-16 | ACTUAL | 2020-07-16 | 2020-07-16 | ACTUAL | 2020-07-16 | null | INTERVENTIONAL | POISE | Only one participant was included | Psoriatic Oligoarthritis Intervention With Symptomatic thErapy | Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study | COMPLETED | null | PHASE4 | 1 | ACTUAL | University of Oxford | Only 1 participants was eligible and participated in the trial during the recruitment period and this patient was lost to follow up after the baseline visit. | 2 | null | null | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | UNDECIDED | Undecided | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04605614 | null | 2020-10-22 | null | null | 2022-06-07 | 2020-10-22 | 2020-10-28 | ACTUAL | null | null | null | null | null | null | 2022-06-07 | 2022-06-09 | ACTUAL | 2022-08-15 | ESTIMATED | 2022-08-15 | 2022-06 | 2022-06-30 | 2024-10-30 | ESTIMATED | 2024-10-30 | 2024-10-30 | ESTIMATED | 2024-10-30 | null | INTERVENTIONAL | null | null | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1 | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | City of Hope Medical Center | null | 1 | null | slow accruals | null | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT02323100 | null | 2014-12-18 | null | null | 2022-03-04 | 2014-12-18 | 2014-12-23 | ESTIMATED | null | null | null | null | null | null | 2022-03-04 | 2022-03-21 | ACTUAL | 2018-12-02 | ACTUAL | 2018-12-02 | 2022-03 | 2022-03-31 | 2022-03-01 | ACTUAL | 2022-03-01 | 2022-03-01 | ACTUAL | 2022-03-01 | null | INTERVENTIONAL | GPBA | null | Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) | A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis | TERMINATED | null | PHASE1/PHASE2 | 13 | ACTUAL | National Jewish Health | null | 3 | null | funding ended | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02589600 | null | 2015-10-27 | 2023-06-16 | null | 2023-09-15 | 2015-10-27 | 2015-10-28 | ESTIMATED | 2023-07-25 | 2023-08-16 | ACTUAL | null | null | null | 2023-09-15 | 2023-09-26 | ACTUAL | 2016-01 | ACTUAL | 2016-01-31 | 2023-09 | 2023-09-30 | 2022-06-22 | ACTUAL | 2022-06-22 | 2022-06-22 | ACTUAL | 2022-06-22 | null | INTERVENTIONAL | ZEST II | Same as participant flow | Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) | ZEST II for Osteoporotic Fracture Prevention | COMPLETED | null | PHASE4 | 310 | ACTUAL | University of Pittsburgh | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,022 | 1 |
NCT03279289 | null | 2017-08-03 | null | null | 2023-04-12 | 2017-09-08 | 2017-09-12 | ACTUAL | null | null | null | null | null | null | 2023-04-12 | 2023-04-13 | ACTUAL | 2017-10-25 | ACTUAL | 2017-10-25 | 2023-04 | 2023-04-30 | 2023-02-09 | ACTUAL | 2023-02-09 | 2023-02-09 | ACTUAL | 2023-02-09 | null | INTERVENTIONAL | AFEMA | null | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen | Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With Metastatic Colorectal Cancer (mCRC) After Failure of an Oxaliplatin-based Regimen | COMPLETED | null | PHASE2 | 170 | ACTUAL | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT02122913 | null | 2014-04-16 | null | null | 2023-11-02 | 2014-04-24 | 2014-04-25 | ESTIMATED | null | null | null | null | null | null | 2023-11-02 | 2023-11-07 | ACTUAL | 2014-05-04 | ACTUAL | 2014-05-04 | 2023-11 | 2023-11-30 | 2021-04-09 | ACTUAL | 2021-04-09 | 2017-02-01 | ACTUAL | 2017-02-01 | null | INTERVENTIONAL | null | null | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors | COMPLETED | null | PHASE1 | 75 | ACTUAL | Bayer | null | 7 | null | null | t | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal. | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | NCT03025360 | APPROVED_FOR_MARKETING | null | null | null | 2,021 | 1 |
NCT03247244 | null | 2017-07-25 | null | null | 2021-01-21 | 2017-08-08 | 2017-08-11 | ACTUAL | null | null | null | null | null | null | 2021-01-21 | 2021-01-25 | ACTUAL | 2018-01-15 | ACTUAL | 2018-01-15 | 2021-01 | 2021-01-31 | 2020-01-27 | ACTUAL | 2020-01-27 | 2019-06-06 | ACTUAL | 2019-06-06 | null | INTERVENTIONAL | null | null | Safety and Efficacy of Cannabis in Tourette Syndrome | A Double-blind, Randomized, Placebo-controlled Crossover Pilot Trial of Medical Cannabis in Adults With Tourette Syndrome | TERMINATED | null | PHASE2 | 15 | ACTUAL | University Health Network, Toronto | null | 4 | null | Recruitment/enrollment took too long | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03602560 | null | 2018-07-18 | 2022-03-23 | null | 2022-07-07 | 2018-07-18 | 2018-07-27 | ACTUAL | 2022-05-04 | 2022-05-31 | ACTUAL | null | null | null | 2022-07-07 | 2022-08-02 | ACTUAL | 2018-10-01 | ACTUAL | 2018-10-01 | 2022-07 | 2022-07-31 | 2020-02-16 | ACTUAL | 2020-02-16 | 2020-02-16 | ACTUAL | 2020-02-16 | null | INTERVENTIONAL | null | null | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | COMPLETED | null | PHASE3 | 265 | ACTUAL | Gilead Sciences | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT02971033 | null | 2016-10-21 | 2022-04-06 | null | 2022-05-10 | 2016-11-18 | 2016-11-22 | ESTIMATED | 2022-05-10 | 2022-06-06 | ACTUAL | null | null | null | 2022-05-10 | 2022-06-06 | ACTUAL | 2018-04-16 | ACTUAL | 2018-04-16 | 2022-05 | 2022-05-31 | 2021-03-31 | ACTUAL | 2021-03-31 | 2021-03-31 | ACTUAL | 2021-03-31 | null | INTERVENTIONAL | null | no patients were randomized to 40mg/day ezetimibe group | Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C | Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C | TERMINATED | null | PHASE2 | 2 | ACTUAL | VA Office of Research and Development | 1. A major limitation is that the study was that it was interrupted by the CoVID-19 pandemic and then was terminated early leading to small numbers of subjects analyzed. It is not possible to derive conclusions comparing the single patients enrolled in arms 1 and 2.~2. The patient in arm 2 had study medication remaining at the first pill count indicating that EZE dosing was lower than 20mg/day during at least part of the treatment period. | 3 | null | Study Funding ended | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | FED | null | null | null | null | null | null | 2,021 | 0 |
NCT03852433 | null | 2019-02-21 | 2024-06-24 | 2023-03-24 | 2024-09-24 | 2019-02-21 | 2019-02-25 | ACTUAL | 2024-07-26 | 2024-07-29 | ACTUAL | null | 2024-07-29 | ACTUAL | 2024-09-24 | 2024-10-08 | ACTUAL | 2019-05-31 | ACTUAL | 2019-05-31 | 2024-09 | 2024-09-30 | 2022-09-28 | ACTUAL | 2022-09-28 | 2022-04-05 | ACTUAL | 2022-04-05 | null | INTERVENTIONAL | null | All Randomized Analysis Set included all participants who were enrolled (informed consent signed) and randomized in the study. | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta | COMPLETED | null | PHASE2 | 175 | ACTUAL | Gilead Sciences | null | 4 | null | null | f | null | null | null | f | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03005184 | null | 2016-12-22 | null | null | 2018-01-09 | 2016-12-22 | 2016-12-29 | ESTIMATED | null | null | null | null | null | null | 2018-01-09 | 2018-01-11 | ACTUAL | 2017-09 | ESTIMATED | 2017-09-30 | 2018-01 | 2018-01-31 | 2020-01 | ESTIMATED | 2020-01-31 | 2020-01 | ESTIMATED | 2020-01-31 | null | INTERVENTIONAL | null | null | Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 | Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Vanderbilt University Medical Center | null | 12 | null | Study is being redesigned and submitted as a new study. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03320876 | null | 2017-10-20 | null | null | 2022-04-20 | 2017-10-20 | 2017-10-25 | ACTUAL | null | null | null | null | null | null | 2022-04-20 | 2022-04-21 | ACTUAL | 2017-07-26 | ACTUAL | 2017-07-26 | 2022-04 | 2022-04-30 | 2021-06-30 | ACTUAL | 2021-06-30 | 2021-06-30 | ACTUAL | 2021-06-30 | null | INTERVENTIONAL | null | null | An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. | A Multicenter, Open-label, Long-term Extension Safety and Efficacy Study of Filgotinib Treatment in Subjects With Moderately to Severely Active Psoriatic Arthritis. | TERMINATED | null | PHASE2 | 122 | ACTUAL | Galapagos NV | null | 1 | null | development program for filgotinib for participants with psoriatic arthritis has been stopped | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT05567952 | null | 2022-10-03 | 2024-09-17 | null | 2024-09-17 | 2022-10-03 | 2022-10-05 | ACTUAL | 2024-09-17 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-17 | 2024-10-08 | ACTUAL | 2022-10-19 | ACTUAL | 2022-10-19 | 2024-09 | 2024-09-30 | 2024-02-09 | ACTUAL | 2024-02-09 | 2023-09-27 | ACTUAL | 2023-09-27 | null | INTERVENTIONAL | null | Full analysis set (FAS) included all participants randomly assigned to study intervention. | A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir | AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY | COMPLETED | null | PHASE2 | 436 | ACTUAL | Pfizer | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 1 |
NCT05329623 | null | 2022-03-29 | null | null | 2024-10-03 | 2022-04-07 | 2022-04-15 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-05-03 | ACTUAL | 2022-05-03 | 2024-10 | 2024-10-31 | 2024-04-07 | ACTUAL | 2024-04-07 | 2024-04-07 | ACTUAL | 2024-04-07 | null | INTERVENTIONAL | null | null | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants. | TERMINATED | null | PHASE1 | 33 | ACTUAL | Novartis | null | 4 | null | Sponsor Decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT02403674 | null | 2015-03-26 | 2018-02-08 | null | 2024-09-30 | 2015-03-26 | 2015-03-31 | ESTIMATED | 2018-03-28 | 2018-04-30 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2015-06-05 | ACTUAL | 2015-06-05 | 2024-09 | 2024-09-30 | 2023-09-07 | ACTUAL | 2023-09-07 | 2017-03-20 | ACTUAL | 2017-03-20 | null | INTERVENTIONAL | DRIVE-AHEAD | The Baseline Analysis Population consists of all randomized participants who received ≥1 dose of study drug. | Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects | COMPLETED | null | PHASE3 | 734 | ACTUAL | Merck Sharp & Dohme LLC | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | http://engagezone.msd.com/ds_documentation.php | YES | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT03822416 | null | 2019-01-28 | 2021-05-03 | null | 2021-05-03 | 2019-01-28 | 2019-01-30 | ACTUAL | 2021-05-03 | 2021-05-25 | ACTUAL | null | null | null | 2021-05-03 | 2021-05-25 | ACTUAL | 2019-03-01 | ACTUAL | 2019-03-01 | 2021-05 | 2021-05-31 | 2020-05-04 | ACTUAL | 2020-05-04 | 2020-05-04 | ACTUAL | 2020-05-04 | null | INTERVENTIONAL | null | null | Treating Smokers With Mental Illness | Treating Tobacco Dependence in Smokers With Severe Mental Illness | COMPLETED | null | PHASE2 | 38 | ACTUAL | University of Minnesota | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT04452006 | null | 2020-06-26 | null | null | 2021-07-06 | 2020-06-26 | 2020-06-30 | ACTUAL | null | null | null | null | null | null | 2021-07-06 | 2021-07-09 | ACTUAL | 2020-07-20 | ACTUAL | 2020-07-20 | 2021-07 | 2021-07-31 | 2021-04-20 | ACTUAL | 2021-04-20 | 2021-04-20 | ACTUAL | 2021-04-20 | null | INTERVENTIONAL | null | null | A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478 | Single-center, Double-blind, Randomized, Placebo-controlled, Three-part, First-in-human, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-541478 in Healthy Subjects | TERMINATED | null | PHASE1 | 56 | ACTUAL | Idorsia Pharmaceuticals Ltd. | null | 11 | null | Based on interim analysis, the Sponsor decided to terminate the study prematurely. | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04927975 | null | 2021-06-11 | 2024-08-27 | 2023-12-12 | 2024-09-30 | 2021-06-11 | 2021-06-16 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | 2024-10-08 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-06-30 | ACTUAL | 2021-06-30 | 2024-09 | 2024-09-30 | 2023-08-29 | ACTUAL | 2023-08-29 | 2023-01-13 | ACTUAL | 2023-01-13 | null | INTERVENTIONAL | null | ITT Population in Period 1 (ITT_1): all randomized participants in Period 1, analyzed according to the treatment groups that they were randomized to. | Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo | COMPLETED | null | PHASE2 | 185 | ACTUAL | AbbVie | null | 5 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/ | Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/ | https://vivli.org/ourmember/abbvie/ | YES | AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT02335944 | null | 2014-10-09 | 2023-01-10 | null | 2023-05-24 | 2015-01-07 | 2015-01-12 | ESTIMATED | 2023-05-24 | 2023-06-18 | ACTUAL | null | null | null | 2023-05-24 | 2023-06-18 | ACTUAL | 2015-01-13 | ACTUAL | 2015-01-13 | 2023-05 | 2023-05-31 | 2020-11-10 | ACTUAL | 2020-11-10 | 2020-11-10 | ACTUAL | 2020-11-10 | null | INTERVENTIONAL | null | No participants were enrolled in Phase II-Group 5 arm due to early study termination. | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer. | TERMINATED | null | PHASE1/PHASE2 | 177 | ACTUAL | Novartis | null | 6 | null | Company decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | YES | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT06102174 | null | 2023-10-06 | null | null | 2024-10-03 | 2023-10-20 | 2023-10-26 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2024-02-15 | ACTUAL | 2024-02-15 | 2024-10 | 2024-10-31 | 2024-09-03 | ACTUAL | 2024-09-03 | 2024-09-03 | ACTUAL | 2024-09-03 | null | INTERVENTIONAL | null | null | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV | AN INTERVENTIONAL, PHASE 1b, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, MULTI-CENTER, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SISUNATOVIR IN PEDIATRIC PARTICIPANTS UP TO AGE 60 MONTHS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT INFECTION (LRTI) | TERMINATED | null | PHASE1 | 10 | ACTUAL | Pfizer | null | 2 | null | Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03361345 | null | 2017-11-17 | null | null | 2023-05-12 | 2017-12-01 | 2017-12-04 | ACTUAL | null | null | null | null | null | null | 2023-05-12 | 2023-05-16 | ACTUAL | 2018-11-01 | ACTUAL | 2018-11-01 | 2023-05 | 2023-05-31 | 2022-01-09 | ACTUAL | 2022-01-09 | 2022-01-09 | ACTUAL | 2022-01-09 | null | INTERVENTIONAL | null | null | Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris | Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | Wayne State University | null | 2 | null | Lack of recruitment | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04816526 | null | 2021-03-23 | 2024-06-27 | null | 2024-09-30 | 2021-03-23 | 2021-03-25 | ACTUAL | 2024-09-30 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-30 | 2024-10-08 | ACTUAL | 2021-12-01 | ACTUAL | 2021-12-01 | 2024-09 | 2024-09-30 | 2022-11-03 | ACTUAL | 2022-11-03 | 2022-08-04 | ACTUAL | 2022-08-04 | null | INTERVENTIONAL | null | null | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | TERMINATED | null | PHASE2 | 13 | ACTUAL | Cartesian Therapeutics | null | 1 | null | Sponsor decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04830462 | null | 2021-03-31 | null | null | 2023-05-15 | 2021-03-31 | 2021-04-05 | ACTUAL | null | null | null | null | null | null | 2023-05-15 | 2023-05-16 | ACTUAL | 2021-04-15 | ACTUAL | 2021-04-15 | 2023-05 | 2023-05-31 | 2023-05-01 | ACTUAL | 2023-05-01 | 2023-05-01 | ACTUAL | 2023-05-01 | null | INTERVENTIONAL | null | null | Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation | Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation | COMPLETED | null | PHASE4 | 32 | ACTUAL | Herlev and Gentofte Hospital | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04700787 | null | 2021-01-06 | null | null | 2022-06-09 | 2021-01-06 | 2021-01-08 | ACTUAL | null | null | null | null | null | null | 2022-06-09 | 2022-06-13 | ACTUAL | 2021-04-30 | ACTUAL | 2021-04-30 | 2022-06 | 2022-06-30 | 2022-04-04 | ACTUAL | 2022-04-04 | 2022-03-25 | ACTUAL | 2022-03-25 | null | INTERVENTIONAL | null | null | Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents | A Phase 1, Multi-Center, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Sulopenem and Sulopenem Etzadroxil + Probenecid in Adolescent Patients With Bacterial Infection | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Iterum Therapeutics, International Limited | null | 1 | null | Enrollment challenges and change in development plan necessitating a change in study design | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT02729714 | null | 2016-01-26 | 2024-06-11 | null | 2024-07-25 | 2016-04-05 | 2016-04-06 | ESTIMATED | 2024-07-25 | 2024-08-20 | ACTUAL | null | null | null | 2024-07-25 | 2024-08-20 | ACTUAL | 2016-04 | ACTUAL | 2016-04-30 | 2024-07 | 2024-07-31 | 2022-04 | ACTUAL | 2022-04-30 | 2022-04 | ACTUAL | 2022-04-30 | null | INTERVENTIONAL | null | null | A Pilot Study of Suvorexant for Insomnia in Parkinson Disease | A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease | COMPLETED | null | PHASE4 | 21 | ACTUAL | Burdick, Daniel, M.D. | Designed as a pilot study, so recruitment goal was low and consequently the sample size is small, limiting interpretation of the significance of the differences between suvorexant and placebo. | 2 | null | null | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDIV | null | null | null | null | null | null | 2,022 | 1 |
NCT05900648 | null | 2023-05-31 | null | null | 2024-04-26 | 2023-05-31 | 2023-06-12 | ACTUAL | null | null | null | null | null | null | 2024-04-26 | 2024-04-29 | ACTUAL | 2023-05-17 | ACTUAL | 2023-05-17 | 2024-04 | 2024-04-30 | 2024-02-09 | ACTUAL | 2024-02-09 | 2024-02-09 | ACTUAL | 2024-02-09 | null | INTERVENTIONAL | null | null | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | M.D. Anderson Cancer Center | null | 1 | null | 0 participant accrual | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT02464657 | null | 2015-06-03 | 2021-06-08 | null | 2021-09-09 | 2015-06-04 | 2015-06-08 | ESTIMATED | 2021-09-09 | 2021-10-07 | ACTUAL | null | null | null | 2021-09-09 | 2021-10-07 | ACTUAL | 2015-07 | ACTUAL | 2015-07-31 | 2021-09 | 2021-09-30 | 2020-05-07 | ACTUAL | 2020-05-07 | 2020-05-07 | ACTUAL | 2020-05-07 | null | INTERVENTIONAL | null | null | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | COMPLETED | null | PHASE1/PHASE2 | 44 | ACTUAL | M.D. Anderson Cancer Center | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT03498391 | null | 2018-03-12 | null | null | 2023-02-06 | 2018-04-06 | 2018-04-13 | ACTUAL | null | null | null | null | null | null | 2023-02-06 | 2023-02-08 | ACTUAL | 2018-07-30 | ACTUAL | 2018-07-30 | 2023-02 | 2023-02-28 | 2023-05 | ESTIMATED | 2023-05-31 | 2023-05 | ESTIMATED | 2023-05-31 | null | INTERVENTIONAL | MSI | null | A Study of Human Multi-Sensory Integration | A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious Perception | SUSPENDED | null | PHASE2 | 40 | ESTIMATED | University of Pennsylvania | null | 2 | null | Due to the impact of COVID-19 | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03996369 | null | 2019-06-21 | 2022-11-28 | null | 2022-11-28 | 2019-06-21 | 2019-06-24 | ACTUAL | 2022-11-28 | 2022-12-21 | ACTUAL | null | null | null | 2022-11-28 | 2022-12-21 | ACTUAL | 2020-09-15 | ACTUAL | 2020-09-15 | 2022-01 | 2022-01-31 | 2021-12-07 | ACTUAL | 2021-12-07 | 2021-12-07 | ACTUAL | 2021-12-07 | null | INTERVENTIONAL | ELEVATE UC 12 | Full Analysis Set: All randomized participants who received at least 1 dose of study intervention. | Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | COMPLETED | null | PHASE3 | 354 | ACTUAL | Arena Pharmaceuticals | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:51:25.715979 | 2024-10-15 06:51:25.715979 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04267276 | null | 2020-02-11 | 2021-12-17 | null | 2022-05-05 | 2020-02-11 | 2020-02-12 | ACTUAL | 2021-12-17 | 2022-02-23 | ACTUAL | null | null | null | 2022-05-05 | 2022-06-01 | ACTUAL | 2020-02-18 | ACTUAL | 2020-02-18 | 2022-05 | 2022-05-31 | 2020-04-02 | ACTUAL | 2020-04-02 | 2020-04-02 | ACTUAL | 2020-04-02 | null | INTERVENTIONAL | null | Treated set (TS): The treated set includes all participants who were entered and treated with one dose of trial drug. The treated set will be used for safety analyses. | A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body | Investigation of Metabolism and Pharmacokinetics of BI 1265162 (C-14) After Intravenous Administration (Part 1) and Investigation of Metabolism and Pharmacokinetics of BI 1265162 (C-14) After Oral Administration (Part 2) in Healthy Male Subjects Following a Non-randomized, Open-label, Single-dose, Single Arm Per Trial Part Mass Balance Design | TERMINATED | null | PHASE1 | 7 | ACTUAL | Boehringer Ingelheim | The study was interrupted due to COVID-19 crisis on 02-Apr-2020, after completion of Part 1. Further, the sponsor decided to discontinue the development of BI 1265162. Enrolment in Part 2 (oral administration of BI 1265162 (C-14)) did not take place. Decision to terminate trial was taken on 17-Dec-2020. | 2 | null | Due to the COVID-19 pandemic, the recruitment of new subjects was temporarily halted in March 2020. The study was permanently discontinued in December 2020. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: http://trials.boehringer-ingelheim.com/ | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT02700841 | null | 2016-03-02 | 2024-01-29 | null | 2024-03-08 | 2016-03-02 | 2016-03-07 | ESTIMATED | 2024-03-08 | 2024-03-12 | ACTUAL | null | null | null | 2024-03-08 | 2024-03-12 | ACTUAL | 2020-01-09 | ACTUAL | 2020-01-09 | 2024-03 | 2024-03-31 | 2022-12-21 | ACTUAL | 2022-12-21 | 2022-12-21 | ACTUAL | 2022-12-21 | null | INTERVENTIONAL | null | null | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation | TERMINATED | null | PHASE2 | 8 | ACTUAL | University of Nebraska | null | 2 | null | Study terminated prematurely due to poor recruitment. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02594111 | null | 2015-10-30 | 2020-06-08 | null | 2023-01-25 | 2015-10-30 | 2015-11-01 | ESTIMATED | 2020-06-26 | 2020-07-10 | ACTUAL | null | null | null | 2023-01-25 | 2023-02-21 | ACTUAL | 2013-05-30 | ACTUAL | 2013-05-30 | 2023-01 | 2023-01-31 | 2021-12-31 | ACTUAL | 2021-12-31 | 2019-08-30 | ACTUAL | 2019-08-30 | null | INTERVENTIONAL | Colchicine-PCI | null | Colchicine in Percutaneous Coronary Intervention | Anti-inflammatory Therapy During Percutaneous Coronary Intervention | COMPLETED | null | PHASE4 | 714 | ACTUAL | VA Office of Research and Development | null | 2 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | FED | null | null | null | null | null | null | 2,021 | 1 |
NCT05512949 | null | 2022-08-20 | 2023-11-30 | 2023-10-25 | 2024-10-03 | 2022-08-20 | 2022-08-23 | ACTUAL | 2024-01-08 | 2024-01-09 | ACTUAL | null | 2024-01-09 | ACTUAL | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-09-09 | ACTUAL | 2022-09-09 | 2022-08-23 | 2022-08-23 | 2023-10-19 | ACTUAL | 2023-10-19 | 2022-12-01 | ACTUAL | 2022-12-01 | null | INTERVENTIONAL | null | null | Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine | A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine | COMPLETED | null | PHASE2 | 229 | ACTUAL | National Institute of Allergy and Infectious Diseases (NIAID) | null | 3 | null | null | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | NIH | null | null | null | null | null | null | 2,023 | 1 |
NCT03345797 | null | 2017-10-10 | null | null | 2023-10-24 | 2017-11-14 | 2017-11-17 | ACTUAL | null | null | null | null | null | null | 2023-10-24 | 2023-10-26 | ACTUAL | 2018-03-01 | ACTUAL | 2018-03-01 | 2023-10 | 2023-10-31 | 2022-04-11 | ACTUAL | 2022-04-11 | 2020-04-11 | ACTUAL | 2020-04-11 | null | INTERVENTIONAL | null | null | Evaluation of Testosterone Nasal Gel in Hypogonadal Boys | A Multicenter, Open Label, Variable Dose, Two Arm Pilot Paediatric Phase 1 PK Study to Evaluate Testosterone Nasal Gel (4.5% w/w) in Hypogonadal Boys | TERMINATED | null | PHASE1 | 8 | ACTUAL | Acerus Pharmaceuticals Corporation | null | 2 | null | Lack of patients and commercial reasons | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04890353 | null | 2021-05-11 | null | null | 2023-10-24 | 2021-05-17 | 2021-05-18 | ACTUAL | null | null | null | null | null | null | 2023-10-24 | 2023-10-25 | ACTUAL | 2021-12-01 | ACTUAL | 2021-12-01 | 2021-05 | 2021-05-31 | 2023-02-28 | ACTUAL | 2023-02-28 | 2023-02-08 | ACTUAL | 2023-02-08 | null | INTERVENTIONAL | null | null | Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke | Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke | TERMINATED | null | PHASE1/PHASE2 | 2 | ACTUAL | Xuanwu Hospital, Beijing | null | 2 | null | The interim analysis of another associated study is not very effective | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03990974 | null | 2019-06-18 | null | null | 2020-03-23 | 2019-06-18 | 2019-06-19 | ACTUAL | null | null | null | null | null | null | 2020-03-23 | 2020-03-25 | ACTUAL | 2020-09 | ESTIMATED | 2020-09-30 | 2020-03 | 2020-03-31 | 2021-07 | ESTIMATED | 2021-07-31 | 2021-06 | ESTIMATED | 2021-06-30 | null | INTERVENTIONAL | HCC | null | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in Hepatocellular Carcinoma After Liver Resection: A Multi-center, Randomized, Open-labelled Trial. | SUSPENDED | null | PHASE3 | 458 | ESTIMATED | Sun Yat-sen University | null | 2 | null | There were difficulties in implementation | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT02819518 | null | 2016-06-28 | 2022-06-08 | null | 2023-11-06 | 2016-06-28 | 2016-06-30 | ESTIMATED | 2022-06-08 | 2022-07-05 | ACTUAL | null | null | null | 2023-11-06 | 2023-11-09 | ACTUAL | 2016-07-27 | ACTUAL | 2016-07-27 | 2023-11 | 2023-11-30 | 2023-10-30 | ACTUAL | 2023-10-30 | 2021-06-15 | ACTUAL | 2021-06-15 | null | INTERVENTIONAL | null | null | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) | COMPLETED | null | PHASE3 | 882 | ACTUAL | Merck Sharp & Dohme LLC | null | 5 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | http://engagezone.msd.com/ds_documentation.php | YES | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT02756663 | null | 2016-04-12 | null | null | 2016-11-07 | 2016-04-26 | 2016-04-29 | ESTIMATED | null | null | null | null | null | null | 2016-11-07 | 2016-11-08 | ESTIMATED | 2016-12 | null | 2016-12-31 | 2016-11 | 2016-11-30 | 2021-02 | ESTIMATED | 2021-02-28 | 2021-02 | ESTIMATED | 2021-02-28 | null | INTERVENTIONAL | PANORAMA-5 | null | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Novartis | null | 3 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT05506930 | null | 2022-08-12 | null | null | 2024-10-03 | 2022-08-17 | 2022-08-18 | ACTUAL | null | null | null | null | null | null | 2024-10-03 | 2024-10-08 | ACTUAL | 2022-08-17 | ACTUAL | 2022-08-17 | 2024-10 | 2024-10-31 | 2024-05-10 | ACTUAL | 2024-05-10 | 2024-05-09 | ACTUAL | 2024-05-09 | null | INTERVENTIONAL | null | null | ITM vs QL for Pediatric Open Lower Abdominal Procedures | Intrathecal Morphine Versus Bilateral Quadratus Lumborum Blocks for Perioperative Analgesia in Pediatric Patients Undergoing Open Lower Abdominal Procedures: A Prospective Randomized Trial | TERMINATED | null | PHASE4 | 14 | ACTUAL | Medical University of South Carolina | null | 2 | null | The study was stopped early based on the anecdotal evidence from a surgeon who felt one group was experiencing more side effects than the other. Exposing pediatric patients who would be assigned to the inferior arm was difficult to justify ethically. | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | null | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT04473950 | null | 2020-06-12 | null | null | 2022-10-06 | 2020-07-13 | 2020-07-16 | ACTUAL | null | null | null | null | null | null | 2022-10-06 | 2022-10-10 | ACTUAL | 2020-01-08 | ACTUAL | 2020-01-08 | 2022-10 | 2022-10-31 | 2022-10-06 | ACTUAL | 2022-10-06 | 2022-10-06 | ACTUAL | 2022-10-06 | null | INTERVENTIONAL | null | null | The Effect of Chronic Pain on Delay Discounting in Methadone Patients | The Effect of Chronic Pain on Delay Discounting in Methadone Patients | TERMINATED | null | PHASE1 | 29 | ACTUAL | University of California, San Francisco | null | 2 | null | The COVID-19 Pandemic prevented us from meeting target goals. | f | null | null | null | f | t | f | null | null | f | null | null | Data will become available after publication of the main study results. | null | null | YES | Data will be made available to the public through presentation at scientific meetings and research publications in peer-reviewed journals. I have routinely kept an open policy to share data with the scientific and medical community upon request, and this policy will be continued with the present project. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02334722 | null | 2015-01-06 | 2021-10-05 | null | 2021-12-14 | 2015-01-06 | 2015-01-08 | ESTIMATED | 2021-12-14 | 2021-12-15 | ACTUAL | null | null | null | 2021-12-14 | 2021-12-15 | ACTUAL | 2015-08-05 | ACTUAL | 2015-08-05 | 2021-12 | 2021-12-31 | 2020-10-07 | ACTUAL | 2020-10-07 | 2020-10-07 | ACTUAL | 2020-10-07 | null | INTERVENTIONAL | null | Subjects were screened against eligibility criteria. Subjects with a history of seizures, depression or use of psychiatric medications, Beck-Depression Inventory score over 14, biopsy only or other factors were determined ineligible. Potential participants who may have been eligible also declined participation. | 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients | A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial | COMPLETED | null | PHASE4 | 81 | ACTUAL | University of Florida | null | 2 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT01891994 | null | 2013-06-28 | 2018-11-14 | null | 2023-04-03 | 2013-06-28 | 2013-07-03 | ESTIMATED | 2018-11-14 | 2018-12-04 | ACTUAL | null | null | null | 2023-04-03 | 2023-04-25 | ACTUAL | 2013-06-28 | null | 2013-06-28 | 2023-03 | 2023-03-31 | 2022-08-24 | ACTUAL | 2022-08-24 | 2017-10-16 | ACTUAL | 2017-10-16 | null | INTERVENTIONAL | null | null | Extended Dosing With Eltrombopag for Severe Aplastic Anemia | Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia | COMPLETED | null | PHASE2 | 40 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 1 | null | null | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | NIH | null | null | null | null | null | null | 2,022 | 1 |
NCT03736785 | null | 2018-11-02 | 2021-02-12 | null | 2021-02-12 | 2018-11-08 | 2018-11-09 | ACTUAL | 2021-02-12 | 2021-03-08 | ACTUAL | null | null | null | 2021-02-12 | 2021-03-08 | ACTUAL | 2018-11-15 | ACTUAL | 2018-11-15 | 2020-03 | 2020-03-31 | 2020-02-18 | ACTUAL | 2020-02-18 | 2020-02-18 | ACTUAL | 2020-02-18 | null | INTERVENTIONAL | null | All randomized participants. | A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus | A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin | COMPLETED | null | PHASE2 | 399 | ACTUAL | Eli Lilly and Company | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting. | A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement. | https://vivli.org/ | YES | Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04430985 | null | 2020-06-08 | null | null | 2021-10-19 | 2020-06-11 | 2020-06-16 | ACTUAL | null | null | null | null | null | null | 2021-10-19 | 2021-10-27 | ACTUAL | 2020-09-30 | ACTUAL | 2020-09-30 | 2021-10 | 2021-10-31 | 2021-09-06 | ACTUAL | 2021-09-06 | 2021-09-06 | ACTUAL | 2021-09-06 | null | INTERVENTIONAL | IMMUNOX | null | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | FOLFOX + Immunotherapy With Intrahepatic Administration of Oxaliplatin for Patients With Multiple Non-resectable Liver Metastasis From Colorectal Cancer | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Herlev Hospital | null | 1 | null | Problems identifying eligble patients | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04011033 | null | 2019-07-03 | 2021-12-23 | null | 2024-09-28 | 2019-07-05 | 2019-07-08 | ACTUAL | 2024-09-28 | 2024-10-08 | ACTUAL | null | null | null | 2024-09-28 | 2024-10-08 | ACTUAL | 2018-03-01 | ACTUAL | 2018-03-01 | 2024-09 | 2024-09-30 | 2023-10-01 | ACTUAL | 2023-10-01 | 2020-03-01 | ACTUAL | 2020-03-01 | null | INTERVENTIONAL | null | null | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | Study of Adoptive Transfer of Invariant Natural Killer T Cells Combined With TAE/TACE to Treat Unresectable Hepatocellular Carcinoma (HCC): Phase II Clinical Trial | COMPLETED | null | PHASE2 | 60 | ACTUAL | Beijing YouAn Hospital | One limitation of our study is that patients only received two cycles of TAE and the duration of iNKT therapy was only 3 months; thus, our study was not long enough to adequately assess OS. A second limitation was the small sample size, but our promising data prompts future studies in larger cohorts to more thoroughly delineate how iNKT cell therapy can be used in the context of TACE/TAE to improve therapeutic options for patients with unresectable HCC. | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 17:01:34.860787 | 2024-10-15 17:01:34.860787 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT05133180 | null | 2021-11-15 | 2024-03-07 | null | 2024-05-10 | 2021-11-15 | 2021-11-24 | ACTUAL | 2024-05-10 | 2024-06-07 | ACTUAL | null | null | null | 2024-05-10 | 2024-06-07 | ACTUAL | 2022-01-19 | ACTUAL | 2022-01-19 | 2024-05 | 2024-05-31 | 2022-12-19 | ACTUAL | 2022-12-19 | 2022-09-22 | ACTUAL | 2022-09-22 | null | INTERVENTIONAL | null | The Full Analysis Set (FAS) population included all patients who were randomized and received at least one dose of the investigational product. | Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) | A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease | COMPLETED | null | PHASE3 | 104 | ACTUAL | Dompé Farmaceutici S.p.A | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04859517 | null | 2021-04-21 | 2024-04-25 | null | 2024-07-25 | 2021-04-23 | 2021-04-26 | ACTUAL | 2024-07-25 | 2024-08-20 | ACTUAL | null | null | null | 2024-07-25 | 2024-08-20 | ACTUAL | 2021-04-27 | ACTUAL | 2021-04-27 | 2024-04 | 2024-04-30 | 2022-11-04 | ACTUAL | 2022-11-04 | 2022-11-04 | ACTUAL | 2022-11-04 | null | INTERVENTIONAL | EVADE | null | Evaluation of ADG20 for the Prevention of COVID-19 | A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE) | TERMINATED | null | PHASE2/PHASE3 | 2,582 | ACTUAL | Invivyd, Inc. | null | 2 | null | All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03850795 | null | 2019-02-20 | null | null | 2024-08-15 | 2019-02-21 | 2019-02-22 | ACTUAL | null | null | null | null | null | null | 2024-08-15 | 2024-08-19 | ACTUAL | 2021-03-15 | ACTUAL | 2021-03-15 | 2024-08 | 2024-08-31 | 2024-06-28 | ACTUAL | 2024-06-28 | 2024-06-28 | ACTUAL | 2024-06-28 | null | INTERVENTIONAL | null | null | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | TERMINATED | null | PHASE3 | 104 | ACTUAL | Hinova Pharmaceuticals USA, Inc. | null | 2 | null | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03733444 | null | 2018-11-05 | 2022-02-16 | null | 2022-07-06 | 2018-11-05 | 2018-11-07 | ACTUAL | 2022-07-06 | 2022-07-29 | ACTUAL | null | null | null | 2022-07-06 | 2022-07-29 | ACTUAL | 2018-11-05 | ACTUAL | 2018-11-05 | 2022-07 | 2022-07-31 | 2021-03-30 | ACTUAL | 2021-03-30 | 2021-03-30 | ACTUAL | 2021-03-30 | null | INTERVENTIONAL | ISABELA2 | Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of investigation product (IP). | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis | TERMINATED | null | PHASE3 | 781 | ACTUAL | Galapagos NV | null | 3 | null | The benefit-risk profile no longer supports continuing the study | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04239872 | null | 2020-01-15 | 2022-03-09 | null | 2023-01-09 | 2020-01-20 | 2020-01-27 | ACTUAL | 2022-06-16 | 2022-06-21 | ACTUAL | null | null | null | 2023-01-09 | 2023-01-31 | ACTUAL | 2020-03-11 | ACTUAL | 2020-03-11 | 2023-01 | 2023-01-31 | 2021-04-05 | ACTUAL | 2021-04-05 | 2021-04-05 | ACTUAL | 2021-04-05 | null | INTERVENTIONAL | null | null | Fluoride Retention in the Mouth of Older Adults | Optimizing Fluoride Retention in the Mouth of Older Adults With Distinct Salivary Flow Rates | COMPLETED | null | PHASE1 | 20 | ACTUAL | University of Michigan | The amount of biofilm collected from participants at the different time points was not enough for all the analyses planned in a number of occasions. This accounts for the lack of data for the calcium concentration in the biofilm fluid.~This experiment was conducted during the COVID-19 pandemic. | 2 | null | null | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT02895373 | null | 2016-06-30 | null | null | 2022-01-25 | 2016-09-05 | 2016-09-09 | ESTIMATED | null | null | null | null | null | null | 2022-01-25 | 2022-02-09 | ACTUAL | 2016-07 | ACTUAL | 2016-07-31 | 2022-01 | 2022-01-31 | 2021-07 | ACTUAL | 2021-07-31 | 2021-05 | ACTUAL | 2021-05-31 | null | INTERVENTIONAL | ECMO_PGE1 | null | PGE1 as Additive Anticoagulant in ECMO-Therapy | A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO) | TERMINATED | null | PHASE2 | 50 | ACTUAL | Medical University of Vienna | null | 2 | null | After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of recruitment and study procedures | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | NO | Data will be published in a peer-reviewed journal, individual data will not be made publicly available except by a direct request to the PI (in an anonymized fashion) | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04308785 | null | 2020-03-12 | null | null | 2023-10-19 | 2020-03-12 | 2020-03-16 | ACTUAL | null | null | null | null | null | null | 2023-10-19 | 2023-10-23 | ACTUAL | 2021-12-01 | ACTUAL | 2021-12-01 | 2023-10 | 2023-10-31 | 2023-07-25 | ACTUAL | 2023-07-25 | 2023-07-25 | ACTUAL | 2023-07-25 | null | INTERVENTIONAL | null | null | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Study to Investigate the Efficacy and Safety of Atezolizumab With or Without Tiragolumab as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed After Chemoradiotherapy | TERMINATED | null | PHASE2 | 24 | ACTUAL | Hoffmann-La Roche | null | 2 | null | The sponsor's decision was based on the negative results of SKYSCRAPER-02. | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | YES | Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). | 2024-10-16 15:47:58.487765 | 2024-10-16 15:47:58.487765 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT04077398 | null | 2019-08-30 | null | null | 2021-02-12 | 2019-09-03 | 2019-09-04 | ACTUAL | null | null | null | null | null | null | 2021-02-12 | 2021-02-16 | ACTUAL | 2020-01-22 | ACTUAL | 2020-01-22 | 2021-02 | 2021-02-28 | 2021-08-01 | ESTIMATED | 2021-08-01 | 2021-01-01 | ESTIMATED | 2021-01-01 | null | INTERVENTIONAL | null | null | Volume vs Concentration: Quadratus Lumborum Blocks With High Volume/Low Concentration or Low Volume/ High Concentration in Nephrectomies | Volume Versus Concentration: a Prospective, Double Blind, Parallel Study to Compare the Clinical Effectiveness of Bilateral Quadratus Lumborum Blocks Using High Volume/Low Concentration or Low Volume/ High Concentration Local Anesthetic in Nephrectomies | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | University of Pittsburgh | null | 2 | null | covid interrupted initial start, then trainees involved finished program and no one took it on | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | there is no plan to share individual participant data. | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04870606 | null | 2021-04-27 | 2023-08-14 | null | 2023-12-11 | 2021-04-29 | 2021-05-03 | ACTUAL | 2023-12-11 | 2024-01-02 | ACTUAL | null | null | null | 2023-12-11 | 2024-01-02 | ACTUAL | 2021-03-05 | ACTUAL | 2021-03-05 | 2023-12 | 2023-12-31 | 2022-04-06 | ACTUAL | 2022-04-06 | 2022-01-24 | ACTUAL | 2022-01-24 | null | INTERVENTIONAL | null | null | Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness | A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness | COMPLETED | null | PHASE3 | 733 | ACTUAL | Suzhou Kintor Pharmaceutical Inc, | null | 2 | null | null | null | null | null | null | null | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT01415674 | null | 2011-08-10 | null | null | 2022-02-01 | 2011-08-11 | 2011-08-12 | ESTIMATED | null | null | null | null | null | null | 2022-02-01 | 2022-02-02 | ACTUAL | 2012-01 | null | 2012-01-31 | 2022-02 | 2022-02-28 | 2021-12 | ACTUAL | 2021-12-31 | 2021-12 | ACTUAL | 2021-12-31 | null | INTERVENTIONAL | PREDICTOR | null | Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients | Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients | COMPLETED | null | PHASE2 | 61 | ACTUAL | UNICANCER | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT03881371 | null | 2019-03-18 | 2022-06-09 | null | 2024-03-14 | 2019-03-18 | 2019-03-19 | ACTUAL | 2024-03-14 | 2024-03-20 | ACTUAL | null | null | null | 2024-03-14 | 2024-03-20 | ACTUAL | 2019-08-01 | ACTUAL | 2019-08-01 | 2024-03 | 2024-03-31 | 2021-08-20 | ACTUAL | 2021-08-20 | 2021-08-20 | ACTUAL | 2021-08-20 | null | INTERVENTIONAL | null | Safety population were included all patients who provided informed consent and received at least 1 dose or partial dose of study drug. | A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa | COMPLETED | null | PHASE3 | 307 | ACTUAL | Zambon SpA | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04362085 | null | 2020-04-20 | null | null | 2021-10-22 | 2020-04-23 | 2020-04-24 | ACTUAL | null | null | null | null | null | null | 2021-10-22 | 2021-10-26 | ACTUAL | 2020-05-11 | ACTUAL | 2020-05-11 | 2021-10 | 2021-10-31 | 2021-10-14 | ACTUAL | 2021-10-14 | 2021-05-10 | ACTUAL | 2021-05-10 | null | INTERVENTIONAL | null | null | Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care | Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) | COMPLETED | null | PHASE3 | 465 | ACTUAL | Unity Health Toronto | null | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03729284 | null | 2018-10-16 | null | null | 2019-10-02 | 2018-11-01 | 2018-11-02 | ACTUAL | null | null | null | null | null | null | 2019-10-02 | 2019-10-04 | ACTUAL | 2020-03-30 | ESTIMATED | 2020-03-30 | 2019-10 | 2019-10-31 | 2020-06-07 | ESTIMATED | 2020-06-07 | 2020-06-07 | ESTIMATED | 2020-06-07 | null | INTERVENTIONAL | null | null | A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta | A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA) COMPARED WITH CYMBALTA(REGISTERED) ( 60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FASTED CONDITIONS | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | Pfizer | null | 2 | null | This study has been cancelled prior to FSFV due to business reasons | f | null | null | null | f | f | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT01007994 | null | 2009-11-04 | 2021-03-07 | null | 2021-04-11 | 2009-11-04 | 2009-11-05 | ESTIMATED | 2021-04-11 | 2021-04-13 | ACTUAL | null | null | null | 2021-04-11 | 2021-04-13 | ACTUAL | 2009-11 | ACTUAL | 2009-11-30 | 2021-04 | 2021-04-30 | 2020-08 | ACTUAL | 2020-08-31 | 2020-01 | ACTUAL | 2020-01-31 | null | INTERVENTIONAL | null | null | Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients | Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients | COMPLETED | null | PHASE2/PHASE3 | 33 | ACTUAL | Northwell Health | null | 2 | null | null | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT05195762 | null | 2021-12-13 | null | null | 2024-05-23 | 2022-01-04 | 2022-01-19 | ACTUAL | null | null | null | null | null | null | 2024-05-23 | 2024-05-28 | ACTUAL | 2023-06 | ESTIMATED | 2023-06-30 | 2024-05 | 2024-05-31 | 2024-12 | ESTIMATED | 2024-12-31 | 2024-06 | ESTIMATED | 2024-06-30 | null | INTERVENTIONAL | null | null | 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi | 12-Week Clinical Study to Determine the Safety, Tolerability, and Clinical Effect of NFX-179 Gel in Subjects With Epidermal Nevi | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Stanford University | null | 1 | null | Sponsored declined to proceed | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | We will only be sharing participant data with the sponsor, Nflection Therapeutics. | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT05644587 | null | 2022-11-21 | null | null | 2024-08-18 | 2022-11-30 | 2022-12-09 | ACTUAL | null | null | null | null | null | null | 2024-08-18 | 2024-08-20 | ACTUAL | 2023-02-06 | ACTUAL | 2023-02-06 | 2024-08 | 2024-08-31 | 2023-11-30 | ACTUAL | 2023-11-30 | 2023-11-30 | ACTUAL | 2023-11-30 | null | INTERVENTIONAL | null | null | Novel Induction to Buprenorphine/Naloxone | Novel Induction to Buprenorphine/Naloxone: A Quasi-Experimental Study With Comparison Group | TERMINATED | null | PHASE4 | 33 | ACTUAL | Bicycle Health | null | 2 | null | Low enrollment numbers | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT00804856 | null | 2008-09-18 | 2022-04-06 | null | 2022-12-02 | 2008-12-08 | 2008-12-09 | ESTIMATED | 2022-12-02 | 2023-10-03 | ACTUAL | null | null | null | 2022-12-02 | 2023-10-03 | ACTUAL | 2008-11-27 | ACTUAL | 2008-11-27 | 2022-12 | 2022-12-31 | 2021-04-23 | ACTUAL | 2021-04-23 | 2012-03-09 | ACTUAL | 2012-03-09 | null | INTERVENTIONAL | null | Treated Set: All patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. For the Phase II part, the treated set (Phase II) was defined as all patients in Phase II who received at least a single dose of either Volasertib or LDAC. | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia | COMPLETED | null | PHASE2 | 180 | ACTUAL | Boehringer Ingelheim | null | 15 | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04028960 | null | 2019-07-19 | 2021-03-03 | null | 2021-04-26 | 2019-07-19 | 2019-07-23 | ACTUAL | 2021-04-26 | 2021-05-18 | ACTUAL | null | null | null | 2021-04-26 | 2021-05-18 | ACTUAL | 2019-10-23 | ACTUAL | 2019-10-23 | 2020-05 | 2020-05-31 | 2020-04-08 | ACTUAL | 2020-04-08 | 2020-04-08 | ACTUAL | 2020-04-08 | null | INTERVENTIONAL | null | Four subjects were enrolled in the study. Two subjects started the study in the placebo arm and the other two started the study in the Humulin-R arm. During the study, each participant crossed over to the opposite arm of the study so that each subject participated in both arms of the study. | IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase | Intranasal Insulin: A Novel Therapy for Hypoglycemia Unawareness in Type 1 Diabetes | TERMINATED | null | PHASE2 | 4 | ACTUAL | HealthPartners Institute | The study team was unable to draw conclusions at this time regarding the cognitive testing performed due to abbreviated funding which led to a small number of subjects analyzed. | 2 | null | Funding was rescinded | null | null | null | null | t | t | f | null | null | t | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03697798 | null | 2018-04-23 | null | null | 2021-01-07 | 2018-10-04 | 2018-10-05 | ACTUAL | null | null | null | null | null | null | 2021-01-07 | 2021-01-08 | ACTUAL | 2018-04-18 | ACTUAL | 2018-04-18 | 2021-01 | 2021-01-31 | 2020-01-14 | ACTUAL | 2020-01-14 | 2020-01-14 | ACTUAL | 2020-01-14 | null | INTERVENTIONAL | BERT | null | A Study Exploring Whooping Cough Protection in Children and Adults | Immunological Effects of an Acellular Pertussis Booster Vaccination in Children, Young Adults and Elderly With Different Immunisation Background. An International Study in Finland, the Netherlands and the United Kingdom | COMPLETED | null | PHASE4 | 122 | ACTUAL | University of Oxford | null | 4 | null | null | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | null | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT05569512 | null | 2022-09-27 | null | null | 2024-08-15 | 2022-10-04 | 2022-10-06 | ACTUAL | null | null | null | null | null | null | 2024-08-15 | 2024-08-19 | ACTUAL | 2022-10-06 | ACTUAL | 2022-10-06 | 2024-08 | 2024-08-31 | 2023-12-06 | ACTUAL | 2023-12-06 | 2023-10-05 | ACTUAL | 2023-10-05 | null | INTERVENTIONAL | null | null | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML | A Phase 1/2 Trial of Uproleselan Combined With High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients With Chemotherapy Resistant Acute Myeloid Leukemia | TERMINATED | null | PHASE1 | 1 | ACTUAL | Dana-Farber Cancer Institute | null | 1 | null | On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2. | f | null | null | null | t | t | f | null | null | null | null | null | Data can be shared no earlier than 1 year following the date of publication | DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu BCH - Contact the Technology \& Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu | null | YES | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04512430 | null | 2020-08-07 | null | null | 2024-08-16 | 2020-08-12 | 2020-08-13 | ACTUAL | null | null | null | null | null | null | 2024-08-16 | 2024-08-20 | ACTUAL | 2020-12-02 | ACTUAL | 2020-12-02 | 2024-08 | 2024-08-31 | 2024-07-19 | ACTUAL | 2024-07-19 | 2024-07-19 | ACTUAL | 2024-07-19 | null | INTERVENTIONAL | null | null | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations | TERMINATED | null | PHASE2 | 4 | ACTUAL | Fundación GECP | null | 1 | null | Low recruitment | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03818581 | null | 2019-01-24 | 2022-11-05 | null | 2024-07-29 | 2019-01-24 | 2019-01-28 | ACTUAL | 2023-02-03 | 2023-03-02 | ACTUAL | null | null | null | 2024-07-29 | 2024-08-20 | ACTUAL | 2019-03-15 | ACTUAL | 2019-03-15 | 2024-07 | 2024-07-31 | 2021-11-03 | ACTUAL | 2021-11-03 | 2021-11-03 | ACTUAL | 2021-11-03 | null | INTERVENTIONAL | null | Four participants in the placebo group dropped out before any baseline or follow-up data could be collected. An additional 4 participants in the treatment group dropped out, leaving only 20 participants with interpretable data. | Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes | Effect of Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes: A Randomized 3-month Clinical Trial Using a Sequential Parallel Comparison Design | COMPLETED | null | PHASE4 | 108 | ACTUAL | Massachusetts General Hospital | null | 4 | null | null | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT05251727 | null | 2022-01-07 | null | null | 2024-08-14 | 2022-02-11 | 2022-02-23 | ACTUAL | null | null | null | null | null | null | 2024-08-14 | 2024-08-19 | ACTUAL | 2022-03-24 | ACTUAL | 2022-03-24 | 2024-08 | 2024-08-31 | 2024-06-05 | ACTUAL | 2024-06-05 | 2024-06-05 | ACTUAL | 2024-06-05 | null | INTERVENTIONAL | null | null | Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients | Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients | TERMINATED | null | PHASE1 | 77 | ACTUAL | Veloxis Pharmaceuticals | null | 6 | null | Business Decision | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03834012 | null | 2019-02-06 | null | null | 2019-07-15 | 2019-02-06 | 2019-02-07 | ACTUAL | null | null | null | null | null | null | 2019-07-15 | 2019-07-17 | ACTUAL | 2019-02 | ESTIMATED | 2019-02-28 | 2019-07 | 2019-07-31 | 2020-04 | ESTIMATED | 2020-04-30 | 2019-11 | ESTIMATED | 2019-11-30 | null | INTERVENTIONAL | null | null | Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma | A Randomized, Parallel Group, Placebo-controlled, Multicenter Phase 3 Study With a PK Sub-group Study With Beclomethasone HFA at 400 μg and 800 μg Daily Doses Compared to Placebo and QVAR in Persistent Asthma. | WITHDRAWN | null | PHASE3 | 0 | ACTUAL | Adamis Pharmaceuticals Corporation | null | 4 | null | Sponsor Decision | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04739358 | null | 2021-01-25 | null | null | 2023-10-17 | 2021-02-01 | 2021-02-04 | ACTUAL | null | null | null | null | null | null | 2023-10-17 | 2023-10-18 | ACTUAL | 2022-05-25 | ACTUAL | 2022-05-25 | 2023-10 | 2023-10-31 | 2023-06-23 | ACTUAL | 2023-06-23 | 2023-06-23 | ACTUAL | 2023-06-23 | null | INTERVENTIONAL | null | null | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | A Phase 1/2 Open-Label Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIs) In Adult Participants With MET-Driven NSCLC | TERMINATED | null | PHASE1/PHASE2 | 2 | ACTUAL | Criterium, Inc. | null | 2 | null | Study was terminated due to lack of lack of enrollment and difficult patient population. | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT02545283 | null | 2015-08-31 | 2021-04-22 | null | 2021-12-28 | 2015-09-08 | 2015-09-09 | ESTIMATED | 2021-08-17 | 2021-09-14 | ACTUAL | null | null | null | 2021-12-28 | 2022-01-11 | ACTUAL | 2015-12-30 | ACTUAL | 2015-12-30 | 2021-12 | 2021-12-31 | 2020-04-24 | ACTUAL | 2020-04-24 | 2020-04-24 | ACTUAL | 2020-04-24 | null | INTERVENTIONAL | MIRROS | null | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | TERMINATED | null | PHASE3 | 447 | ACTUAL | Hoffmann-La Roche | null | 2 | null | The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT05395052 | null | 2022-05-13 | null | null | 2023-09-19 | 2022-05-25 | 2022-05-27 | ACTUAL | null | null | null | null | null | null | 2023-09-19 | 2023-09-21 | ACTUAL | 2022-05-31 | ACTUAL | 2022-05-31 | 2023-09 | 2023-09-30 | 2023-08-11 | ACTUAL | 2023-08-11 | 2023-08-11 | ACTUAL | 2023-08-11 | null | INTERVENTIONAL | null | null | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors | TERMINATED | null | PHASE1 | 5 | ACTUAL | Fate Therapeutics | null | 6 | null | This study was terminated by the Sponsor. | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT02782104 | null | 2016-04-29 | 2023-12-29 | null | 2024-02-16 | 2016-05-20 | 2016-05-25 | ESTIMATED | 2024-02-16 | 2024-02-20 | ACTUAL | null | null | null | 2024-02-16 | 2024-02-20 | ACTUAL | 2016-06-09 | ACTUAL | 2016-06-09 | 2024-02 | 2024-02-29 | 2022-12-30 | ACTUAL | 2022-12-30 | 2022-12-30 | ACTUAL | 2022-12-30 | null | INTERVENTIONAL | SUSTAIN-3 | null | A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | COMPLETED | null | PHASE3 | 1,148 | ACTUAL | Janssen Research & Development, LLC | null | 1 | null | null | f | null | null | null | t | null | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03850522 | null | 2019-02-19 | null | null | 2022-04-08 | 2019-02-20 | 2019-02-21 | ACTUAL | null | null | null | null | null | null | 2022-04-08 | 2022-04-15 | ACTUAL | 2019-02-18 | ACTUAL | 2019-02-18 | 2022-04 | 2022-04-30 | 2021-03-10 | ACTUAL | 2021-03-10 | 2021-03-10 | ACTUAL | 2021-03-10 | null | INTERVENTIONAL | null | null | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma | TERMINATED | null | PHASE2 | 6 | ACTUAL | Herlev Hospital | null | 1 | null | Insufficient recruitment within planned enrolmentperiod. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04442503 | null | 2020-06-18 | 2023-04-11 | null | 2023-11-27 | 2020-06-18 | 2020-06-22 | ACTUAL | 2023-06-21 | 2023-06-22 | ACTUAL | null | null | null | 2023-11-27 | 2023-11-30 | ACTUAL | 2020-06-08 | ACTUAL | 2020-06-08 | 2023-11 | 2023-11-30 | 2022-04-12 | ACTUAL | 2022-04-12 | 2022-03-15 | ACTUAL | 2022-03-15 | null | INTERVENTIONAL | null | Safety Set included all participants who were administered Investigational product (IP). | A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) | A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression | COMPLETED | null | PHASE3 | 200 | ACTUAL | Biogen | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | https://vivli.org/ | YES | In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/ | 2024-10-16 15:54:15.550997 | 2024-10-16 15:54:15.550997 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03797612 | null | 2019-01-06 | null | null | 2020-07-09 | 2019-01-06 | 2019-01-09 | ACTUAL | null | null | null | null | null | null | 2020-07-09 | 2020-07-13 | ACTUAL | 2021-01 | ESTIMATED | 2021-01-31 | 2020-07 | 2020-07-31 | 2022-02 | ESTIMATED | 2022-02-28 | 2022-01 | ESTIMATED | 2022-01-31 | null | INTERVENTIONAL | null | null | Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores | A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of Brivoligide Injection in Patients With a Pain Catastrophizing Scale Score ≥16 Undergoing Unilateral Total Knee Arthroplasty | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Adynxx, Inc. | null | 2 | null | Study initiation delayed due to COVID 19 | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | Individual participant data will not be made available to other researchers. | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT01860404 | null | 2013-05-20 | 2024-01-29 | null | 2024-04-17 | 2013-05-20 | 2013-05-22 | ESTIMATED | 2024-04-17 | 2024-05-14 | ACTUAL | null | null | null | 2024-04-17 | 2024-05-14 | ACTUAL | 2014-01 | ACTUAL | 2014-01-31 | 2024-04 | 2024-04-30 | 2023-01 | ACTUAL | 2023-01-31 | 2023-01 | ACTUAL | 2023-01-31 | null | INTERVENTIONAL | HIT_HEADS | Includes all 42 patients randomized | BCAA Supplementation for Concussion | Head Injury Treatment With Healthy and Advanced Dietary Supplements (HIT HEADS): A Randomized, Placebo-controlled, Double-blinded, Therapeutic Exploratory Clinical Trial of Branched Chain Amino Acids (BCAA's) in the Treatment of Concussion | COMPLETED | null | PHASE2 | 42 | ACTUAL | Children's Hospital of Philadelphia | There are several key limitations to our study that necessitate a larger, more definitive trial. Due to a combination of initially more strict inclusion criteria, and the impact of the coronavirus pandemic, our sample size was smaller than anticipated. This, combined with poorer than expected follow-up, led us to have to use alternative statistical analytic methods. We were further limited by missing data. This also necessitated the alternative analytic approach / post-hoc analysis. | 5 | null | null | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 02:36:11.649977 | 2024-10-17 02:36:11.649977 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04810962 | null | 2021-03-18 | 2023-06-15 | null | 2023-07-12 | 2021-03-19 | 2021-03-23 | ACTUAL | 2023-06-15 | 2023-07-07 | ACTUAL | null | null | null | 2023-07-12 | 2023-07-25 | ACTUAL | 2021-03-16 | ACTUAL | 2021-03-16 | 2023-07 | 2023-07-31 | 2022-07-06 | ACTUAL | 2022-07-06 | 2022-07-06 | ACTUAL | 2022-07-06 | null | INTERVENTIONAL | null | Intent-to-Treat Population | Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study | A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study | COMPLETED | null | PHASE3 | 370 | ACTUAL | Formosa Pharmaceuticals, Inc. | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:42:19.961335 | 2024-10-17 02:42:19.961335 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |